Login to Your Account

CRDAC: Serelaxin exciting but more study is needed

By Mari Serebrov
Washington Editor

Thursday, March 27, 2014
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) unanimously voted against recommending approval for Novartis AG’s serelaxin based on the strength of a single pivotal trial in acute heart failure (AHF).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription